This public meeting, convened under a cooperative agreement between the Robert J. Margolis, MD, Center for Health Policy at Duke University and the U.S. Food and Drug Administration, will explore the state of the science of clinical research evaluating medication adherence involving FDA-regulated products. Specific topics include: -Current landscape of interventions intended to (a) track (monitor) medication adherence, (b) improve medication adherence, and (c) improve clinical outcome(s) due to increased medication adherence;
-Measurements of medication adherence; and
-Study designs to evaluate the effectiveness of FDA-regulated products intended to track and/or improve medication adherence, with or without an association to clinical outcomes.
0 Comments